Curocell Grants 114,300 Stock Options to 85 Employees... Exercise Price at Premium Limits Dilution Concerns
Curocell decided on May 27, 2026 via board resolution to grant 114,300 common stock options to 85 employees.
The exercise price is 44,900 won, approximately 24.6% above the closing price of 36,050 won on the day before grant, setting a premium that limits dilution concerns for existing shareholders.
The exercise period runs from May 27, 2028 to May 27, 2038, with a 2-year vesting period before exercise is allowed.
With this grant, total outstanding stock options increase to 1,352,515 shares, representing 8.54% of total issued shares.
The options are granted via issuance of new shares, subject to shareholder approval.
The fair value was calculated using the binomial model, with per-share values of 22,375 won and 23,091 won for respective vesting tranches.
[AI Comprehensive Analysis]This stock option grant is a routine procedure for employee incentives. The exercise price being above the current market price means no immediate dilution, but if the stock price rises in the future, potential dilution may materialize. The total grant size of 8.54% of issued shares could be a long-term burden on shareholder value.